MCF7/ExeR-2 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
MCF7/ExeR-1 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (4)
- Inventor Info
Info
| Catalogue Number | 152555 |
| Antigen/Gene or Protein Targets | Exemestane resistance |
| Parental Line | MCF7 |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast Cancer |
| Relevance | The MCF7/ExeR-1 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors.Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the steroidal AI exemestane allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment. |
| Production Details | Exemestane-resistant cell lines were established from MCF-7 cells grown in medium with 10% NCS and 10−7 M testosterone. A culture of MCF-7 cells were treated with 10−7 M exemestane for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with exemestane. After ~2–3 months, the isolated colonies gave rise to exemestane-resistant cell lines, which could be grown in exemestane-containing medium with a weekly split ratio of ~1:25. The MCF-7 cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF-7 cell line. |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Breast cancer cell line resistant to the aromatase inhibitor exemestane. Estrogen receptor positive. Progesterone receptor positive when grown in medium without exemestane. |
| Recommended Growing Conditions | Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM exemestane. |
| Notes |
Human breast cancer cell line derived from MCF-7 cells Other related cell lines: - LetR-1, LetR-2, LetR-3 and LetR-4 resistant to the non-steroidal AI letrozole - ExeR-2, ExeR-3 and ExeR-4 resistant to the steroidal AI exemestane - AnaR-1, AnaR-2, AnaR-3 and AnaR-4 resistant to the non-steroidal AI anastrozole Passage 430 (AL3058, AL3059) |
| Cellosaurus ID | CVCL_5A13 |
MCF7/ExeR-3 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
MCF7/ExeR-4 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
References: 4 entries
Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.
Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Europe PMC ID: 25667100
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Europe PMC ID: 25625755
Add a reference
References: 4 entries
Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.
Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Add a reference
